Impact of a non-fluoridated microcrystalline hydroxyapatite dentifrice on enamel caries progression in highly caries-susceptible orthodontic patients: A randomized, controlled 6-month trial.

Ulrich SchlagenhaufKarl-Heinz KunzelmannChristian HannigTheodor W MayHelmut HöslMario GratzaGabriele ViergutzMarco NazetSebastian SchambergerPeter Proff

Published in: Journal of investigative and clinical dentistry (2019)

In highly caries-active patients, the impact of the regular use of a microcrystalline HAP dentifrice on caries progression is not significantly different from the use of a 1400 ppm fluoride toothpaste (ClinicalTrials.gov: NCT02705456).

Keyphrases

end stage renal disease
newly diagnosed
oral health
chronic kidney disease
ejection fraction
prognostic factors
clinical trial
peritoneal dialysis
randomized controlled trial
patient reported outcomes
double blind